The funding round was led by Boston Fun One Way Ventures and long-time health tech angel investor Esther Dyson among others. Esther Dyson’s primary activity is investing in start-ups and guiding many of them as a board member. Her board seats include Boxbe, CVO Group (Hungary), Eventful.com, Evernote, IBS Group (Russia, advisory board), Meetup, Midentity (UK), NewspaperDirect, and WPP Group and Yandex (Russia).
Humanity will be utilizing the funds to combine digital and biomedical biomarkers into a consumer app that they are going to launch next year. Digital biomarkers include heart rate, weight etc., while biomedical markers are basically the cholesterol levels, body temperature, blood pressure and others. Humanity seeks to combine these two to get a 360-degree view of how our body is functioning.
Founded by Peter Ward and Michael Geer in 2019, Humanity Inc. is developing a software application designed to provide information on how to stop the ageing process by leveraging AI. It allows people to try different interventions and solutions to help move those biomarkers in a positive direction and thus reduce or stop the loss of function and thus the ageing damage.
Ward and Geer aim to “help humanity live healthier, longer lives, monitor their actual rate of ageing”. They wish to provide solutions so that people can potentially reverse their ageing process.
“People have never had an accurate clear feedback loop to help them know whether what they’re doing to be healthier was really working or not. We want to finally give them that superpower,” said Michael Geer in a statement.
Their Science Advisory Board includes George Church and Aubrey de Grey, some of the leading names in the field of genetics. George Church is a Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard and MIT, and a founding member of the Wyss Institute for Biologically Inspired Engineering. De Grey is a biomedical gerontologist. She is also the Chief Science Officer of the SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics.
Humanity Inc. is conducting tests of its Alpha product on several users. The app will launch in UK and USA in early 2021 and globally in 2022.